

PATENT/DOCKET NO. PC22004B

Appl. No. 10/761,636

Filing Date: January 21, 2004

Reply to Office action of February 8, 2006

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) A veterinary formulation suitable for topical application or spot-on application for administration to companion animals comprising selamectin at around 1% to 16% w/v, and praziquantel at around 0.5-10%w/v, in a veterinarily acceptable carrier, diluent or adjuvant.
2. (Canceled)
3. (Original) The formulation according to claim 1 wherein the praziquantel is present at around 6% w/v.
- 4.(Original) The formulation according to claim 1 which further comprises a di(C₃₋₄ glycol) mono(C₁₋₄ alkyl) ether and an optional skin-acceptable solvent.
5. (Canceled)
6. (Currently amended) The formulation according to claim 1 wherein said selamectin is provided at around 6-12mg/kg ₁ {with respect to the host animal ₁ } and praziquantel is provided at up to 18mg/kg ₁ { with respect to the host animal }.
7. (Previously Presented) The formulation according to claim 1 wherein said selamectin is present at about 6% to about 12% w/v.
8. (original) The formulation according to claim 1 wherein the praziquantel is present in the formulation at about 3% to about 9% w/v.
9. (Canceled)

FORM AMEND
Rev. 5/27/03

~~PATENT~~/Docket No. PC22004B

Appl. No. 10/761,636

Filing Date: January 21, 2004

Reply to Office action of February 8, 2006

10. (Currently amended) The formulation according to claim 1 wherein a di(C₂₋₄ glycol) mono(C₁₋₄ alkyl) ether is present, said ether being diethylene glycol monomethyl ether (DEGMME) or dipropylene glycol monomethyl ether (DPGMME).

11. (Original) The formulation according to claim 1 wherein a skin-acceptable solvent is present, said solvent being ethanol or isopropanol.

12. (Currently amended) A formulation according to claim 1 which consists of:

- (a) selamectin, at a level of 1% to 16% w/v;
 - (b) DEGMME or DPGMME at 1 to 16% w/v, and at a w/v or v/v ratio of active compound to DEGMME/DPGMME of about 1:1;
 - (c) praziquantel at 0.5 to 10% w/v;
 - (d) isopropanol to volume (100%);
- and, optionally (e) BHT (at less than 0.1% w/v).

13. (Currently amended) A method of treatment and prophylaxis of parasitic infestation of flea, heartworm ~~or and treatment~~ of tapeworm in a mammal which comprises administering a topical application or spot-on application to said mammal an amount of selamectin, and an amount of praziquantel, each amount being effective to treat or provide prophylaxis to the mammal.

14. (Previously Presented) The method according to claim 13 wherein the selamectin and praziquantel are administered separately in different formulations.

15. (Previously Presented) The method according to claim 13 wherein selamectin, and praziquantel are administered in the same formulation.

16. (Previously Presented) The method according to claim 13 wherein the selamectin, and praziquantel are administered via the same route.

17. (Previously Presented) A method of treatment according to claim 13 wherein the selamectin, and praziquantel are administered via different routes.

FORM AMEND
Rev. 5/27/03

~~PATENT~~/Docket No. PC22004B

Appl. No. 10/761,636

Filing Date: January 21, 2004

Reply to Office action of February 8, 2006

18. (original) The method according to claim 13 wherein the mammal is a companion animal, selected from the group consisting of a cat.

19. (Currently amended) A kit useful in the treatment of or prophylaxis of a parasitic infestation of flea, heartworm or and treatment of tapeworm in a mammal, which comprises selamectin, and praziquantel and a pharmaceutical or veterinary carrier, and instructions for the treatment of a parasitic infestation of flea, heartworm or tapeworm in a mammal, where said instructions include the requirement of a topical application or spot-on application of said selamectin, and praziquantel.

FORM AMEND
Rev. 5/27/03